{"id":745080,"date":"2015-11-06T14:13:00","date_gmt":"2015-11-06T14:13:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/"},"modified":"2025-11-07T01:24:49","modified_gmt":"2025-11-07T06:24:49","slug":"merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/","title":{"rendered":"Merck Statement on FDA Advisory Committee Meeting for BRIDION\u00ae (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium"},"content":{"rendered":"<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today issued the following statement after the conclusion of a meeting<br \/>\n      of the Anesthetic and Analgesic Drug Products Advisory Committee of the<br \/>\n      U.S. Food and Drug Administration (FDA) to discuss BRIDION<sup>\u00ae<\/sup><br \/>\n      (sugammadex). BRIDION is the proposed trade name for Merck\u2019s<br \/>\n      investigational agent for the reversal of neuromuscular blockade (NMB)<br \/>\n      induced by rocuronium or vecuronium.\n    <\/p>\n<p>\n      \u201cWe believe that BRIDION has the potential to offer anesthesia<br \/>\n      professionals an important new option to reverse neuromuscular blockade<br \/>\n      in the surgical setting,\u201d said Dr. David Michelson, head of global<br \/>\n      clinical development for neuroscience, Merck Research Laboratories.<br \/>\n      \u201cToday\u2019s discussion is one step in the regulatory process, and we look<br \/>\n      forward to working with the FDA as it completes the review of our New<br \/>\n      Drug Application for BRIDION.\u201d\n    <\/p>\n<p>\n      The FDA is not bound by the committee\u2019s guidance but takes its advice<br \/>\n      into consideration when reviewing investigational medicines. The<br \/>\n      Prescription Drug User Fee Act (PDUFA) action date for the FDA\u2019s review<br \/>\n      of BRIDION is Dec. 19, 2015.\n    <\/p>\n<p>\n      If approved, BRIDION would be the first in a new class of medicines,<br \/>\n      known as selective relaxant binding agents, to be used in the U.S.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51219484&amp;newsitemid=20151106005937&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=1&amp;md5=3663e31e6e52f5a87ec5e9f3edbeb2a4\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51219484&amp;newsitemid=20151106005937&amp;lan=en-US&amp;anchor=Twitter&amp;index=2&amp;md5=6d711bf6ea989415575507162a3c22ae\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51219484&amp;newsitemid=20151106005937&amp;lan=en-US&amp;anchor=Facebook&amp;index=3&amp;md5=b2c91f0a8ec28d735c5877dade74ac90\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51219484&amp;newsitemid=20151106005937&amp;lan=en-US&amp;anchor=YouTube&amp;index=4&amp;md5=9f5ae6b7d89bdf61069654694abf4704\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, NJ, USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the United States Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of the company\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51219484&amp;newsitemid=20151106005937&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=5&amp;md5=9ae331e144b4f1c69b1d48207d6994f6\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151106005937r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Doris Li,        908-740-1903<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss BRIDION \u00ae (sugammadex). BRIDION is the proposed trade name for Merck\u2019s investigational agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. \u201cWe believe that BRIDION has the potential to offer anesthesia professionals an important new option to reverse neuromuscular blockade in the surgical setting,\u201d said Dr. David Michelson, head of global clinical development for neuroscience, Merck Research Laboratories. \u201cToday\u2019s discussion is one step in the regulatory process, and we look forward to working with the FDA as it completes the review of our New Drug Application for BRIDION.\u201d The FDA is not bound by the committee\u2019s guidance but takes its advice into consideration when reviewing<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745080","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Statement on FDA Advisory Committee Meeting for BRIDION\u00ae (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Statement on FDA Advisory Committee Meeting for BRIDION\u00ae (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss BRIDION \u00ae (sugammadex). BRIDION is the proposed trade name for Merck\u2019s investigational agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. \u201cWe believe that BRIDION has the potential to offer anesthesia professionals an important new option to reverse neuromuscular blockade in the surgical setting,\u201d said Dr. David Michelson, head of global clinical development for neuroscience, Merck Research Laboratories. \u201cToday\u2019s discussion is one step in the regulatory process, and we look forward to working with the FDA as it completes the review of our New Drug Application for BRIDION.\u201d The FDA is not bound by the committee\u2019s guidance but takes its advice into consideration when reviewing\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\\\/\",\"name\":\"Merck Statement on FDA Advisory Committee Meeting for BRIDION\u00ae (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-11-06T14:13:00+00:00\",\"dateModified\":\"2025-11-07T06:24:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Statement on FDA Advisory Committee Meeting for BRIDION\u00ae (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Statement on FDA Advisory Committee Meeting for BRIDION\u00ae (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/","og_locale":"en_US","og_type":"article","og_title":"Merck Statement on FDA Advisory Committee Meeting for BRIDION\u00ae (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued the following statement after the conclusion of a meeting of the Anesthetic and Analgesic Drug Products Advisory Committee of the U.S. Food and Drug Administration (FDA) to discuss BRIDION \u00ae (sugammadex). BRIDION is the proposed trade name for Merck\u2019s investigational agent for the reversal of neuromuscular blockade (NMB) induced by rocuronium or vecuronium. \u201cWe believe that BRIDION has the potential to offer anesthesia professionals an important new option to reverse neuromuscular blockade in the surgical setting,\u201d said Dr. David Michelson, head of global clinical development for neuroscience, Merck Research Laboratories. \u201cToday\u2019s discussion is one step in the regulatory process, and we look forward to working with the FDA as it completes the review of our New Drug Application for BRIDION.\u201d The FDA is not bound by the committee\u2019s guidance but takes its advice into consideration when reviewing","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:49+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/","name":"Merck Statement on FDA Advisory Committee Meeting for BRIDION\u00ae (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-11-06T14:13:00+00:00","dateModified":"2025-11-07T06:24:49+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-meeting-for-bridion-sugammadex-investigational-agent-for-the-reversal-of-neuromuscular-blockade-nmb-induced-by-rocuronium-or-vecuronium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Statement on FDA Advisory Committee Meeting for BRIDION\u00ae (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9c23eaf0-7448-4f3a-8de0-eca13ed8fd7a","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745080\/revisions"}],"predecessor-version":[{"id":3674576,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745080\/revisions\/3674576"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745080"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}